Company intelligence / Profile preview
iTeos Therapeutics
Watertown, Massachusetts, United Statesiteostherapeutics.com ↗
- Ownership
- Public · ITOS
- Employees
- ~100
- Development stage
- Phase 3
01
Overview
iTeos has multiple clinical programs with promising results. Their GALAXIES Lung-201 trial with belrestotug (EOS-448) + dostarlimab in NSCLC has interim data expected in Q2 2025. The company recently deprioritized inupadenant despite showing a 63.9% overall response rate and 7.7 months median PFS in Phase 2 for NSCLC.
- Therapeutic areas
- Oncology
- Modalities
- Antibodies (including IgG1)Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
GSK (dostarlimab combination trials)
Beyond the preview
Go deeper on iTeos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iTeos Therapeutics.